BioNTech BNTX · NASDAQ
$87.99 +1.07% (+$0.93)
Summary
30 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: 9.74B € against 316.0M €.
- The share price is below the Bulios Fair Price.
- Out of every 100 EUR of revenue, 20 EUR is left as free cash.
What to watch
- Revenue fell by 46% a year over the last 3 years.
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 35% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 42% a year over 5 years. Over the last 3 years it fell by 46% a year. For the next fiscal year analysts expect revenue to fall by 35%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of 1.69B €.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 20
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $121.83 is 38% above today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other Sales 100%
By region
- UNITED STATES 63%
- GERMANY 26%
- IRELAND 11%
- Rest of the World 0.4%
Other Sales brings in 100% of revenue.
Segments in detail